Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ACT
2026-526028-38-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Planned start Oct 2026; status: authorised.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2026-526028-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526028-38-00.